Drugs / AZD5851
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06084884 | Dec 2023 → Dec 2027 expected | hepatocellular carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD5851 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06084884 ↗ |
| Modality | Cell therapy | “Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against GPC3” NCT06084884 ↗ |
| Route | Intravenous | “administered by intravenous (IV) infusion” NCT06084884 ↗ |
| Target | GPC3 | “Chimeric Antigen Receptor T-Cell (CAR-T) Therapy Directed Against GPC3” NCT06084884 ↗ |